Historically ion channels have been among the most attractive targets for therapeutic intervention. But discovery of new ion channel drugs has come to a halt because ion channels are difficult to assay, require specialized tools and skills to study adequately, and have historically been impossible to study directly in high-throughput mode-the preferred style of the last decade. Now, a variety of automated assay technologies are coming on the market that should increase throughput, and some drug discovery companies have developed proprietary high-throughput methods for in-house use. With industry now interested more than ever in applying higher-throughput technologies to precedented targets, in a sense, ion channel discovery may become a beneficiary of the failures of genomics, combinatorial chemistry, and high-throughput screening.
By Marc Wortman
In a talk at the Yale University School of Medicine this past February, Edward Scolnick, MD, president emeritus of Merck...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.
The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.
Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.
Yeytuo will have remaining challenges to PrEP to overcome, while Kisunla’s label reflects dosing titration data from a Phase IIIb study to mitigate ARIA-E.
Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.
With a US approval any time soon now looking unlikely, analysts are revising Blenrep’s peak sales guidance downwards.
